Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.

Eur J Hum Genet 2004 Nov;12(11):899-906

Department of Oncology, Transplants and New Technologies in Medicine, Section of Pathology, University of Pisa, Pisa, Italy.

Accurate estimates of breast and ovarian cancer penetrance in BRCA1/2 mutation carriers are crucial in genetic counseling. Estimation is difficult because of the low frequency of mutated alleles and the often-uncertain mechanisms of family ascertainment. We estimated the penetrances of breast and ovarian cancers in carriers of BRCA1/2 mutations by maximizing the retrospective likelihood of the genetic model, given the observed test results, in 568 Italian families screened for germline mutations. The software BRCAPRO was used as a probability calculation tool in a Markov Chain Monte Carlo approach. Breast cancer penetrances were 27% (95% CI 20-34%) at age 50 years and 39% (27-52%) at age 70 in BRCA1 carriers, and 26% (0.18-0.34%) at age 50 and 44% (29-58%) at age 70 in BRCA2 carriers, and ovarian cancer penetrances were 14% (7-22%) at age 50 and 43% (21-66%) at age 70 in BRCA1 carriers and 3% (0-7%) at age 50 and 15% (4-26%) at age 70 in BRCA2 carriers. The new model gave a better fit than the current default in BRCAPRO, the likelihood being 70 log units greater; in addition, the observed numbers of mutations in families stratified by gene and by cancer profile were not significantly different from those expected. Our new penetrance functions are appropriate for predicting breast cancer risk, and for determining the probability of carrying BRCA1/2 mutations, in people who are presently referred to genetic counseling in Italy. Our approach could lead to country-customized versions of the BRCAPRO software by providing appropriate population-specific estimates.

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.ejhg.5201256DOI Listing
November 2004
5 Reads

Publication Analysis

Top Keywords

brca1/2 mutations
12
ovarian cancer
12
breast ovarian
12
breast cancer
8
genetic counseling
8
cancer penetrances
8
brca1 carriers
8
brca2 carriers
8
age brca2
8
age brca1
8
age
8
penetrances breast
8
carriers
6
cancer
6
mutations
5
penetrances 14%
4
14% 7-22%
4
7-22% age
4
carriers ovarian
4
44% 29-58%
4

References

(Supplied by CrossRef)
Article in J Clin Oncol
A Martin et al.
J Clin Oncol 2001
Article in Am J Hum Genet
D Ford et al.
Am J Hum Genet 1998
Article in Am J Hum Genet
CI Szabo et al.
Am J Hum Genet 1997
Article in J Natl Cancer Inst
J Peto et al.
J Natl Cancer Inst 1999
Article in J Natl Cancer Inst
N Loman et al.
J Natl Cancer Inst 2001
Article in J Natl Cancer Inst
GS Dite et al.
J Natl Cancer Inst 2003
Article in Int J Cancer
S de Sanjose et al.
Int J Cancer 2003
Article in Am J Hum Genet
HA Risch et al.
Am J Hum Genet 2001
Article in Dis Markers
J Chang-Claude et al.
Dis Markers 1999
Article in Semin Surg Oncol
SE Karp et al.
Semin Surg Oncol 2000
Article in JAMA
W Burke et al.
JAMA 1997

Similar Publications